Shares of Sonoma Pharmaceuticals Inc (NASDAQ:SNOA) have earned an average broker rating score of 2.00 (Buy) from the two brokers that provide coverage for the stock, Zacks Investment Research reports. One analyst has rated the stock with a hold rating and one has assigned a strong buy rating to the company. Sonoma Pharmaceuticals’ rating score has declined by 100% in the last three months as a result of various analysts’ upgrades and downgrades.
Brokerages have set a 12 month consensus price target of $8.00 for the company and are expecting that the company will post ($0.65) EPS for the current quarter, according to Zacks. Zacks has also assigned Sonoma Pharmaceuticals an industry rank of 204 out of 265 based on the ratings given to related companies.
Several equities analysts have issued reports on the stock. Zacks Investment Research upgraded shares of Sonoma Pharmaceuticals from a “hold” rating to a “buy” rating and set a $6.25 target price on the stock in a research note on Wednesday, January 10th. Maxim Group restated a “buy” rating and set a $7.00 target price (down previously from $11.00) on shares of Sonoma Pharmaceuticals in a research note on Wednesday, February 14th. Finally, Benchmark started coverage on shares of Sonoma Pharmaceuticals in a research note on Thursday, December 28th. They issued a “speculative buy” rating and a $10.00 price objective on the stock.
Sonoma Pharmaceuticals stock traded down $0.17 on Friday, reaching $3.77. 52,471 shares of the company’s stock traded hands, compared to its average volume of 51,950. The company has a quick ratio of 3.83, a current ratio of 4.62 and a debt-to-equity ratio of 0.01. The company has a market cap of $18.26, a PE ratio of -1.35 and a beta of 1.24. Sonoma Pharmaceuticals has a 1-year low of $3.50 and a 1-year high of $8.25.
Sonoma Pharmaceuticals (NASDAQ:SNOA) last posted its earnings results on Wednesday, February 7th. The company reported ($0.73) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.63) by ($0.10). The company had revenue of $4.84 million for the quarter, compared to the consensus estimate of $4.50 million. Sonoma Pharmaceuticals had a negative net margin of 70.46% and a negative return on equity of 70.95%. research analysts forecast that Sonoma Pharmaceuticals will post -2.86 earnings per share for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: “Sonoma Pharmaceuticals Inc (SNOA) Receives Consensus Rating of “Buy” from Brokerages” was originally reported by Sports Perspectives and is the property of of Sports Perspectives. If you are reading this article on another website, it was copied illegally and republished in violation of U.S. and international copyright legislation. The original version of this article can be accessed at https://sportsperspectives.com/2018/03/21/sonoma-pharmaceuticals-inc-snoa-receives-consensus-rating-of-buy-from-brokerages.html.
About Sonoma Pharmaceuticals
Sonoma Pharmaceuticals, Inc, formerly Oculus Innovative Sciences, Inc, is a specialty pharmaceutical company that develops and markets solutions for the treatment of dermatological conditions and advanced tissue care. The Company’s product portfolio consists of dermatology and advanced tissue care products based upon its technologies, such as Microcyn and Lipogrid.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Sonoma Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sonoma Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.